Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas

Human Pathology

Volumn 44, Issue 10, 2013, Pages 2323-2330

  Chaux, Alcides ^a,b   Albadine, Roula ^a,c   Schultz, Luciana ^a   Hicks, Jessica ^a   Carducci, Michael A ^a   Argani, Pedram ^a   Allaf, Mohamad ^a   Netto, George J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Gral Santos E/ 25 de Mayo   (Paraguay)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

4EBP1; AKT; Chromophobe renal cell carcinoma; HIF 1 ; mTOR; PTEN; S6

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN S6;

ADULT; ARTICLE; CANCER MORTALITY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; PARTIAL NEPHRECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

4EBP1; AKT; CHROMOPHOBE RENAL CELL CARCINOMA; HIF-1Α; MTOR; PTEN; S6;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MARYLAND; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84884418061     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.05.014     Document Type: Article

References (23)

1. T. Klatte, and A.J. Pantuck Molecular biology of renal cortical tumors Urol Clin North Am 35 2008 573 580 [vi]
2. L. Schultz, A. Chaux, and R. Albadine Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas Am J Surg Pathol 35 2011 1549 1556
3. C. Coppin, C. Kollmannsberger, L. Le, F. Porzsolt, and T.J. Wilt Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials BJU Int 108 2011 1556 1563
4. P. Mulders Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms BJU Int 104 2009 1585 1589
5. E.A. Singer, G. Bratslavsky, W.M. Linehan, and R. Srinivasan Targeted therapies for non-clear renal cell carcinoma Target Oncol 5 2010 119 129
6. A.M. Molina, D.R. Feldman, and M.S. Ginsberg Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma Invest New Drugs 30 2012 335 340
7. T. Klatte, D.B. Seligson, and S.B. Riggs Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma Clin Cancer Res 13 2007 7388 7393
8. A.S. Merseburger, J. Hennenlotter, and U. Kuehs Activation of PI3K is associated with reduced survival in renal cell carcinoma Urol Int 80 2008 372 377
9. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2007 2257 2267
10. B. Shuch, S. Vourganti, J.C. Friend, L.M. Zehngebot, W.M. Linehan, and R. Srinivasan Targeting the mTOR pathway in Chromophobe Kidney Cancer J Cancer 3 2012 152 157
11. B. Kucejova, S. Pena-Llopis, and T. Yamasaki Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma Mol Cancer Res 9 2011 1255 1265
12. S. Eggener TNM staging for renal cell carcinoma: time for a new method Eur Urol 58 2010 517 519 [discussion 519-521]
13. H.L. Fedor, and A.M. De Marzo Practical methods for tissue microarray construction Methods Mol Med 103 2005 89 101
14. S.K. Tickoo, D. Alden, and S. Olgac Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma J Urol 177 2007 1258 1263
15. T.L. Lotan, B. Gurel, and S. Sutcliffe PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Clin Cancer Res 17 2011 6563 6573
16. A. Chaux, L. Schultz, and R. Albadine Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas Hum Pathol 43 2012 2129 2137
17. B. Paule, and N. Brion Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy Anticancer Res 31 2011 331 333
18. D. Zardavas, A. Meisel, and P. Samaras Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer Case Rep Oncol 4 2011 16 18
19. J.M. Larkin, R.A. Fisher, and L.M. Pickering Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus J Clin Oncol 29 2011 e241 242
20. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
21. W.M. Stadler, R.A. Figlin, and D.F. McDermott Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280
22. E.R. Plimack, E. Jonasch, B.N. Bekele, W. Qiao, C.S. Ng, and N.M. Tannir Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study [abstract] J Clin Oncol 28 2010 15 [Abstract #4604]
23. R.L. Camp, V. Neumeister, and D.L. Rimm A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers J Clin Oncol 26 2008 5630 5637